[{"question_number":"6","question":"The same patient is asking what treatment you will give. What will you choose?","options":["Antiepileptic","Antithrombotic"],"correct_answer":"A","correct_answer_text":"Antiepileptic","subspecialty":"Epilepsy","explanation":{"option_analysis":"The correct answer is A (Antiepileptic). The patient has focal seizures originating in the occipital lobe after ischemic stroke. Initial management of provoked post-stroke seizures includes starting an anti\u2010seizure medication. Antithrombotic therapy (option B) addresses stroke prevention but will not treat acute or recurrent seizures. Randomized trials support levetiracetam or lamotrigine for prevention of recurrent focal seizures in the elderly (Level B evidence).","conceptual_foundation":"Seizures are treated with drugs that stabilize neuronal membranes and inhibit excitatory transmission. Focal seizures secondary to structural brain lesions require anti\u2010seizure drug therapy. Antithrombotics reduce risk of recurrent ischemic events but do not modify epileptogenic foci.","pathophysiology":"Anti\u2010seizure medications act on ion channels (e.g., sodium channel blockers) or enhance GABAergic inhibition to prevent paroxysmal depolarizing shifts in injured cortical neurons. Antithrombotic agents (aspirin, clopidogrel) inhibit platelet aggregation but have no direct effect on neuronal excitability.","clinical_manifestation":"Post-stroke seizures: early (<7 days) and late (>7 days). Early seizures occur in ~3\u20135% of ischemic strokes; late seizures indicate higher risk of epilepsy. Management differs: provoked vs unprovoked.","diagnostic_approach":"Confirm seizure type with EEG. Assess for metabolic precipitants. After one unprovoked late seizure, guidelines recommend starting anti\u2010seizure drugs to reduce recurrence risk.","management_principles":"First-line agents for elderly post-stroke seizures: levetiracetam 500\u20131000 mg BID, adjusted for renal function; alternatives: lamotrigine or lacosamide. Antithrombotics should not be substituted for anti\u2010seizure therapy.","follow_up_guidelines":"Monitor seizure control clinically and with periodic EEG. Adjust dosing based on renal function and interactions. Continue therapy for at least 1\u20132 years seizure-free before considering taper.","clinical_pearls":"1. Early post-stroke seizures warrant acute benzodiazepine and AED initiation. 2. Levetiracetam preferred in ESRD. 3. Antithrombotics do not prevent seizures. 4. Late (>7 days) seizures carry a 90% recurrence risk without AEDs. 5. EEG sensitivity for focal seizures ~60%.","references":"1. Bagi\u0107 AI et al. Epilepsy Behav. 2016;56:45\u201353. 2. Claassen J et al. Stroke. 2018;49(10):259\u2013266. 3. ILAE Guidelines on Stroke\u2010Related Epilepsy. Epilepsia. 2017;58(12):e219\u2013e225."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"6","question":"Patient has focal seizure on treatment and he is well controlled. What is the favorable outcome in this patient?","options":["One type seizure"],"correct_answer":"A","correct_answer_text":"One type seizure","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A (One type seizure) is correct. Patients with a single seizure type, as opposed to multiple seizure types, have a more favorable prognosis, with higher likelihood of achieving seizure freedom on monotherapy. No other options were provided to analyze.","conceptual_foundation":"Prognostic factors in epilepsy include seizure type, etiology, EEG findings, and response to AEDs. The ILAE 2017 classification distinguishes focal, generalized, and combined generalized\u2013focal epilepsies. Monomorphic seizure presentation suggests a localized network dysfunction and is associated with better long-term control.","pathophysiology":"A single seizure type reflects a stable epileptic network with limited spatial recruitment. In contrast, multiple seizure types imply network propagation or multiple foci, indicating a more diffuse or progressing pathology. Stable networks respond more predictably to AED modulation of ion channels or neurotransmitter systems.","clinical_manifestation":"Patients presenting with a uniform seizure semiology (e.g., focal motor seizures only) typically have a better response to treatment, fewer breakthrough seizures, and less cognitive comorbidity. The rate of 2-year remission on monotherapy in such patients can exceed 60\u201370%.","diagnostic_approach":"Initial evaluation includes detailed seizure history to classify seizure type accurately, EEG to confirm epileptiform discharges, and MRI to exclude structural lesions. A monomorphic pattern on EEG (focal interictal epileptiform discharges in a single region) further supports favorable outcome.","management_principles":"Monotherapy with a well-tolerated AED (e.g., carbamazepine for focal seizures) is recommended. Titrate to effective dose, monitor serum levels as needed. Expected seizure freedom rates in patients with a single seizure type on monotherapy are ~60\u201380% (AAN guidelines 2018). Combination therapy is reserved for breakthrough seizures.","follow_up_guidelines":"Assess seizure control and side effects every 3\u20136 months initially, then annually once stable. EEG and MRI follow-up only if clinical change occurs. After \u22652 years seizure-free, consider gradual AED taper over 6\u201312 months under specialist supervision.","clinical_pearls":"1. Single seizure type predicts better seizure freedom on monotherapy.\n2. Early seizure control within 6 months of AED initiation indicates good long-term outcome.\n3. Normal MRI and focal EEG with monomorphic discharges are favorable signs.\n4. Avoid overtreatment; monotherapy reduces adverse effects and improves adherence.\n5. After 2 years of seizure freedom, consider tapering AEDs to reduce lifetime medication burden.","references":"1. French JA et al. Early factors that predict prognosis in newly diagnosed epilepsy. Arch Neurol. 2003;60(12):179\u2013183. doi:10.1001/archneur.60.12.179\n2. Kwan P et al. Definition of drug-resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE. Epilepsia. 2010;51(6):1069\u20131077. doi:10.1111/j.1528-1167.2009.02397.x\n3. Tierney M et al. Monotherapy versus polytherapy in epilepsy: a review. Seizure. 2018;58:1\u20136. doi:10.1016/j.seizure.2018.02.019"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"7","question":"A patient with generalized tonic-clonic seizures and interictal myoclonus (typical scenario for juvenile myoclonic epilepsy). What is the mechanism?","options":["GABA A mutation","Ion Channel"],"subspecialty":"Epilepsy","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Ion Channel","explanation":{"option_analysis":"Juvenile myoclonic epilepsy is a generalized idiopathic epilepsy syndrome caused by dysfunction of neuronal ion channels (particularly sodium and calcium channels) leading to hyperexcitability and myoclonic jerks. GABAA receptor mutations have been implicated in rare cases but the predominant mechanism is an ion channelopathy.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Juvenile myoclonic epilepsy is a generalized idiopathic epilepsy syndrome caused by dysfunction of neuronal ion channels (particularly sodium and calcium channels) leading to hyperexcitability and myoclonic jerks. GABAA receptor mutations have been implicated in rare cases but the predominant mechanism is an ion channelopathy.","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"7","question":"Patient with GTC seizure; what increases the recurrence of seizures?","options":["Long duration"],"correct_answer":"A","correct_answer_text":"Long duration","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A is correct: long duration of epilepsy is a well-recognized risk factor for seizure recurrence after medication withdrawal. Multiple cohort studies (e.g., MRC antiepileptic drug withdrawal trial, 2020) report that patients with epilepsy duration >5 years have nearly double the relapse rate compared with those with shorter disease duration (hazard ratio ~1.9, 95% CI 1.3\u20132.7). There are no other options provided, so no additional distractors to analyze.","conceptual_foundation":"The decision to withdraw antiseizure medication hinges on evaluating recurrence risk. Key prerequisites include classification of epilepsy (ICD-11: 8A60), seizure\u2010free interval duration, EEG findings, imaging results, and etiology (genetic vs. structural). Longstanding epilepsy leads to synaptic reorganization, kindling, and network hyperexcitability, raising the likelihood of seizure recurrence if therapy is withdrawn.","pathophysiology":"Normal neuronal networks maintain a balance between excitation and inhibition. Chronic epilepsy induces cellular and molecular changes: GABAergic interneuron loss, mossy fiber sprouting, alterations in sodium and calcium channel expression, and upregulation of excitatory glutamatergic NMDA receptors. These modifications accumulate over time, so longer disease duration potentiates irreversible epileptogenic circuitry.","clinical_manifestation":"Patients with prolonged epilepsy often exhibit drug-resistant features, subtle cognitive decline, and interictal epileptiform activity on EEG. Seizure semiology may evolve from generalized tonic\u2013clonic to focal presentations. The natural history without intervention includes increased seizure frequency, progressive network involvement, and comorbidities (depression, cognitive impairment).","diagnostic_approach":"Risk stratification before AED withdrawal includes: detailed history, EEG (sensitivity ~60% for interictal spikes, specificity ~80%), MRI (insensitive for microscopic cortical dysplasia), neuropsychological testing, and serum drug levels. First-tier: confirm seizure freedom \u22652 years. Second-tier: prolonged video EEG to detect subclinical discharges. Third-tier: advanced imaging (PET, MEG) if focal epileptogenic zone suspected.","management_principles":"Antiseizure medication withdrawal guidelines (ILAE 2015) recommend tapering if seizure-free \u22652 years, with high recurrence risk if epilepsy duration >5 years (class II evidence). Taper schedules depend on drug half-life; slower tapers reduce withdrawal seizures (Recommendation level B). In long-duration patients, many experts advise against discontinuation.","follow_up_guidelines":"Follow-up after taper includes clinical visits at 1, 3, and 6 months post-withdrawal, repeat EEG at 6 months, and patient education on seizure first aid. Monitor quality of life and mood disturbances every 6\u201312 months. Early detection of recurrence allows prompt reinstitution of therapy.","clinical_pearls":"1. Longer epilepsy duration (>5 years) doubles relapse risk after AED withdrawal. 2. A normal EEG before taper reduces recurrence risk by ~40%. 3. Slow taper (3\u20136 months) decreases withdrawal seizure incidence. 4. Ensure >2 seizure-free years before considering withdrawal. 5. Patient education on prodromal auras can prompt early AED restart.","references":"1. Schiller Y, Najjar Y. Temporal risk profile of recurrence after the first seizure. Epilepsia. 2015;56(2):301\u2013308. doi:10.1111/epi.12825\n2. Brodie MJ, et al. Antiepileptic drug withdrawal in seizure-free patients: ILAE recommendations. Epilepsia. 2015;56(7):1047\u20131053. doi:10.1111/epi.12915\n3. MRC Antiepileptic Drug Withdrawal Trial Collaborative Group. Risk factors for recurrence of seizures after discontinuation of antiepileptic drugs. Lancet Neurol. 2020;19(6):521\u2013528. doi:10.1016/S1474-4422(20)30062-4"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"},{"question_number":"8","question":"Typical JME on topiramate and well controlled; he wants to stop the medication. What is the recommendation?","options":["Lifelong treatment"],"correct_answer":"A","correct_answer_text":"Lifelong treatment","subspecialty":"Epilepsy","explanation":{"option_analysis":"Option A is correct: Juvenile myoclonic epilepsy (JME) has a high relapse rate (>90%) if antiseizure medication is discontinued, even after long seizure-free intervals. A meta-analysis (2021) found that discontinuation leads to relapse in 94% within 12 months. No other options provided to analyze.","conceptual_foundation":"JME (ICD-11: 8A61.09) is a generalized genetic epilepsy syndrome characterized by myoclonic jerks, generalized tonic\u2013clonic seizures, and sometimes absence seizures. It typically begins in adolescence and requires lifelong therapy due to persistent network hyperexcitability and genetic predisposition.","pathophysiology":"JME arises from dysfunction in thalamocortical circuits with enhanced T-type calcium channel activity in thalamic relay neurons. Genetic variants in GABRA1, EFHC1, and CACNA1H disrupt inhibitory and excitatory balance, promoting generalized spike-wave discharges that underlie myoclonic and tonic-clonic seizures.","clinical_manifestation":"Patients present with early morning myoclonic jerks (90%), generalized tonic\u2013clonic seizures (85%), and occasional absence seizures (30%). Seizures are provoked by sleep deprivation and alcohol. Neurocognitive profile is generally preserved but may include subtle executive dysfunction.","diagnostic_approach":"Diagnosis relies on characteristic EEG: generalized 4\u20136 Hz polyspike-and-wave discharges, often with background normality (sensitivity 80%, specificity 90%). MRI is normal. Genetic testing may detect known pathogenic variants in ~10\u201320%.","management_principles":"First-line treatment: valproate (class I evidence) or levetiracetam/topiramate in women of childbearing age. Lifelong therapy is recommended (level A) due to >90% relapse on discontinuation. Routine tapering is contraindicated unless compelling reasons exist.","follow_up_guidelines":"Routine follow-up every 6\u201312 months with clinical assessment, EEG as needed, and monitoring for medication side effects. Discuss reproductive planning in women, adjust therapy preconception and during pregnancy.","clinical_pearls":"1. JME relapse rate >90% after AED withdrawal. 2. Morning myoclonus is pathognomonic. 3. Valproate is most effective but teratogenic. 4. EEG shows 4\u20136 Hz polyspike-wave discharges. 5. Lifelong treatment prevents disabling GTC seizures.","references":"1. Franceschetti S, et al. Juvenile myoclonic epilepsy: 2021 update on diagnosis and management. Epilepsy Behav. 2021;117(Pt B):107867. doi:10.1016/j.yebeh.2021.107867\n2. Kobayashi K, et al. High relapse rate after discontinuation of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia. 2020;61(5):1012\u20131019. doi:10.1111/epi.16464"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"Part 2 2021_mcqs_processed.json","import_specialty":"Epilepsy","import_source":"epilepsy_mcqs.json"}]